The Oncology Institute, Inc. (STLN) - Total Assets
Based on the latest financial reports, The Oncology Institute, Inc. (STLN) holds total assets worth $178.23 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see cash efficiency ratio of The Oncology Institute, Inc. for how efficiently the company converts equity into cash flow.
The Oncology Institute, Inc. - Total Assets Trend (2022–2025)
This chart illustrates how The Oncology Institute, Inc.'s total assets have evolved over time, based on quarterly financial data. See STLN stock price for real-time trading data and today's change.
The Oncology Institute, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
The Oncology Institute, Inc.'s total assets of $178.23 Million consist of 68.5% current assets and 31.5% non-current assets. Explore working capital position of The Oncology Institute, Inc. to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.4% |
| Accounts Receivable | $59.00 Million | 35.8% |
| Inventory | $16.88 Million | 10.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.02 Million | 6.7% |
| Goodwill | $7.23 Million | 4.4% |
Asset Composition Trend (2022–2025)
This chart illustrates how The Oncology Institute, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: The Oncology Institute, Inc.'s current assets represent 68.5% of total assets in 2025, an increase from 49.8% in 2022.
- Cash Position: Cash and equivalents constituted 20.4% of total assets in 2025, up from 5.4% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 14.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 35.8% of total assets.
The Oncology Institute, Inc. Competitors by Total Assets
Key competitors of The Oncology Institute, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
FRESENIUS SE+CO. ADR 1/4
F:FREA
|
Germany | €41.40 Billion |
|
Sejahteraraya Anugrahjaya Tbk
JK:SRAJ
|
Indonesia | Rp7.64 Trillion |
|
Surgery Partners Inc
NASDAQ:SGRY
|
USA | $7.95 Billion |
|
Huaxia Eye Hospital Group Co. Ltd. A
SHE:301267
|
China | CN¥8.17 Billion |
|
Regis Healthcare Ltd
AU:REG
|
Australia | AU$2.11 Billion |
|
Hospital Mater Dei S.A
SA:MATD3
|
Brazil | R$4.38 Billion |
|
Bait Bakfar Ltd
TA:BKFR
|
Israel | ILA2.25 Billion |
|
Pacific Smiles Group Ltd
AU:PSQ
|
Australia | AU$163.53 Million |
The Oncology Institute, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.36 | 1.62 | 1.79 |
| Quick Ratio | 1.15 | 1.37 | 1.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $34.05 Million | $40.01 Million | $47.28 Million |
The Oncology Institute, Inc. - Advanced Valuation Insights
This section examines the relationship between The Oncology Institute, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 74.34 |
| Latest Market Cap to Assets Ratio | 3.89 |
| Asset Growth Rate (YoY) | -4.7% |
| Total Assets | $164.66 Million |
| Market Capitalization | $640.89 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values The Oncology Institute, Inc.'s assets at a significant premium (3.89x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: The Oncology Institute, Inc.'s assets decreased by 4.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for The Oncology Institute, Inc. (2022–2025)
The table below shows the annual total assets of The Oncology Institute, Inc. from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $164.66 Million | -4.67% |
| 2024-12-31 | $172.72 Million | -17.46% |
| 2023-12-31 | $209.24 Million | -20.04% |
| 2022-12-31 | $261.67 Million | -- |
About The Oncology Institute, Inc.
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educatio… Read more